Tolerance of Human Fibroblasts to Benfo-Oxythiamine In Vitro

Ming Yan, Ralf Smeets, Martin Gosau, Tobias Vollkommer, Sandra Fuest, Eva Stetzer, Lan Kluwe, Johannes F. Coy and Simon Burg
Additional contact information
Ming Yan: Department of Oral and Maxillofacial Surgery, Guiyang Hospital of Stomatology, Guiyang 550002, China
Ralf Smeets: Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Martin Gosau: Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Tobias Vollkommer: Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Sandra Fuest: Department of Oral and Maxillofacial Surgery, Division of “Regenerative Orofacial Medicine”, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Eva Stetzer: Benfovir AG, 64293 Darmstadt, Germany
Lan Kluwe: Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Johannes F. Coy: Benfovir AG, 64293 Darmstadt, Germany
Simon Burg: Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

IJERPH, 2022, vol. 19, issue 7, 1-9

Abstract: Objectives: To explore the potential application of B-OT in the aspiration tract. Materials and Methods: We conceived and optimized an in vitro model simulating the mouth-washing process to assess tolerance to B-OT on primary human gingival fibroblasts. Cells derived from 4 unrelated donors were flushed with medium containing drugs of various concentration for one minute twice daily for 3 days. Results: No effect was seen on the cells up to 1000 µM B-OT. In addition, we treated the cells with B-OT permanently in medium, corresponding to a systemic treatment. No effect was seen by 10 µM B-OT and only a slight reduction (approximately 10%) was seen by 100 µM B-OT. Conclusions: Our results suggest good tolerance of oral cells for B-OT, favoring the further development of this antiviral reagent as a mouth-washing solution and nasal spray.

Keywords: benfo-oxythiamine; fibroblast; SARS-CoV-2; virus replication (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/7/4112/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/7/4112/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:7:p:4112-:d:783602

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().